Idiopathic Thrombocytopenic Purpura
Conditions
Keywords
ITP
Brief summary
To determine the long term effects of pulse high dose dexamethasone and conventional dose prednisolone in treatment of adult patients with ITP.
Detailed description
Patients will be randomized to one of two study arms: dexamethasone 40 mg po daily for 4 consecutive days. If the platelet count drops below 30X109/L after response within 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering (Arm 1). Prednisone 1 mg/kg po daily for 4-8 weeks, the drug is then decreased slowly over another few weeks (Arm 2).
Interventions
DRUGDexamethasone
Pulse high dose dexamethasone (Arm 1) 1. Patients will receive 40 mg of oral dexamethasone daily for four consecutive days. 2. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14 3. If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given. 4. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering. 5. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments.
DRUGPrednisolone
Conventional dose prednisone (Arm 2) 1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter. 2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months
Sponsors
Cooperative Study Group A for Hematology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * a true thrombocytopenia on blood smear * adequate megakaryopoiesis on bone marrow examination * the absence of clinically apparent associated conditions or cause of thrombocytopenia * Age over 16 years * A platelet count of less than 30x109/L
Exclusion criteria
: * previous treatment for ITP. * other causes of thrombocytopenia such as HIV infection, lymphproliferative disease, liver disease, or definite SLE. * Patients with life threatening bleeding and pregnant women should be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| response rate and platelet count | 6 years | Endpoint definitions and criteria for evaluation: This study is designed to compare the effectiveness of high dose dexamethasone with conventional dose prednisone for patient with ITP. The effectiveness will be evaluated in terms of response rate and platelet count at 6 months after the treatment |
Countries
South Korea
Outcome results
None listed